Could Alkermes’ new antipsychotic punch below its weight?
Approval of ALKS 3831 looks likely after Friday’s positive panel vote, but sales might disappoint.
Bristol bets big on Myokardia
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.
Go or no go? Vaccine panel upstages US approval decisions
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Another strong year for novel drug approvals is in the making
Few signs of a tightening regulatory climate can be found in approval numbers for 2020 – but some big decisions are still pending.
